The UK's largest pharmacy chain is launching a medical cannabis service
Boots, the UK's largest pharmacy chain, is entering the medical cannabis market with SureLeaf, a private online prescription service.
Boots Adds Medical Cannabis to Its Lineup
On November 16, 2026, Boots UK announced the launch of SureLeaf, thereby becoming the first major British chain of neighborhood pharmacies to offer a service dedicated to medical cannabis prescriptions.
Accessible via Boots Online Doctor, the platform allows eligible patients aged 25 and older to consult with medical specialists and, if appropriate, obtain prescriptions for cannabis. Although Boots operates more than 1,800 stores nationwide, prescriptions will not be filled at local pharmacies. Instead, the products will be delivered directly to patients through a centralized distribution system.
This initiative marks a significant shift in a sector that has thus far been dominated by specialized private clinics, eight years after the legalization of medical cannabis in the UK, in November 2018. This breakthrough is all the more significant given that access through the public health care system remains extremely limited, with barely five patients who have a prescription covered by the NHS.
Who is eligible for Boots' medical cannabis service?
SureLeaf is intended for patients whose symptoms have not been adequately controlled by conventional treatments. Eligible conditions include fibromyalgia, arthritis, neuropathic pain, sciatica, chronic migraines, pelvic pain associated with endometriosis, generalized anxiety disorder, and insomnia.
Patients must first complete an online medical questionnaire before participating in a video consultation with a doctor listed in the registry of specialists of the General Medical Council. Any proposed treatment plan must then be approved by a multidisciplinary clinical team, including a second consultant. The treatment is monitored, with an initial follow-up after 28 days, followed by appointments at least every three months.
Unlike many British clinics specializing in cannabis that accept adults aged 18 and older, SureLeaf excludes young adults under the age of 25, regardless of their medical history.
Explaining this decision to leafie, a Boots spokesperson said, «We set the minimum age at 25 at launch as part of a deliberately cautious approach.»
How much does medical cannabis cost at Boots?
SureLeaf is offering a launch package priced at 89 £, including a consultation with a specialist and an initial prescription for’cannabis oil when clinically indicated. An annual care package costs 99 £, with medications billed separately.
Medical cannabis flowers start at £38 for 5 grams, while cannabis oils are available starting at £35 for 10 mL.
The initial catalog includes 11 flower-based products and four oils; no further information is available at this time, other than that they were selected based on clinical considerations.
The University of Nottingham will analyze the results in patients
Alongside its commercial launch, Boots is exploring a research collaboration with the’University of Nottingham. The program will examine prescribing practices, patient experiences, and clinical outcomes, particularly in the management of chronic pain. The researchers aim to strengthen the scientific evidence regarding cannabis-based medications and to identify the patients who are likely to benefit the most from them.
Dr. David Gwynne, medical director of Boots Online Doctor, explained the importance of clinical caution:
«Medical cannabis is not suitable for everyone, and decisions regarding its prescription must be made with caution, on a case-by-case basis.»
A Turning Point for the U.K. Medical Cannabis Market?
According to industry estimates, there are between 60,000 and 75,000 active patients using medical cannabis In the United Kingdom, most prescriptions are filled by the private sector. The arrival of Boots could raise public awareness of legal treatment options, while introducing a well-established pharmaceutical brand to a relatively specialized market.
It also reflects growing institutional acceptance, though it does not fundamentally resolve the obstacles to broader patient access.
-
Business4 weeks ago
Cronos Completes the Acquisition of CanAdelaar for 57.5 million euros
-
Cannabis in Quebec3 weeks ago
Cannabis: What France Could Learn from Quebec, Eight Years After Legalization
-
Cannabis in New Zealand3 weeks ago
Chronic Pain: New Zealand Is Testing Cannabis to Improve Sleep
-
Cannabis in Morocco4 weeks ago
Morocco: Three Cannabis-Based Medications Approved for the Treatment of Epilepsy
-
Cannabis in France3 weeks ago
Dr. Pascal Douek, a tireless advocate for medical cannabis in France, has died
-
Business4 weeks ago
The Brazilian medical cannabis market continues to grow
-
Cannabis in Spain4 weeks ago
Spain: Medical Cannabis Is Coming to About 50 Hospitals
-
Cannabis in France3 weeks ago
Medical cannabis: The Greens introduce two amendments to accelerate its widespread adoption


You must be logged in to post a comment Login